🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

DURBAC trial- BVAC vaccine + Durvalumab in recurrent/met after 1L therapy for HPV16/18+ cervical cancer shows ORR 38% with median DOR 8.7months. Could ADCs also raise their response rates with addition of immunotherapy to compete? #ASCO24

Final OS results from the SOC-1 trial are out: after adjusting for crossover, secondary cytoreduction followed by chemo in selected patients with plat sensitive EOC (via iModel score) resulted in improved OS compared to standard chemo #gynscm #ovariancancer #ASCO24

Our MD Anderson Cancer Center Gyn Oncology faculty and fellow team presenting our work at #ASCO24! #oncsurgery #endcancer

#gynonc #fellows at #ASCO24 🫡 Reporting for duty at poster session!

#ASCO24 AGO 2.29 chemo+bev +/- atezo: once again CPI fail to meaningfully impact survival. Front line: ATHENA COMBO reported negative in press release this week, Plat sensitive: ATALANTE and ANITA both negative and now second plat resistant study neg. Time to move on....

Distillations to Deepdish 🍕in Chicago ASCO #ASCO24 !!! Moffitt Cancer Center Dr. Patrick Hwu Robert Wenham Jeffrey How Anne Knisely, MD

Come to poster #494b in the Gyn poster session #ASCO24 to learn more about our phase 1/2 TROP2 directed CAR NK cell trial now enrolling at MD Anderson Cancer Center! Amir Jazaeri Katy Rezvani, M.D., Ph.D

🔥🔥Trial in progress MD Anderson Cancer Center Phase I/II study TROP2 CAR engineered IL-15 NK cells delivered IP in recurrent #ovariancancer Anne Knisely, MD Amir Jazaeri #ASCO24 #gyncsm

Had a great time at #ASCO24 learning from giants in our field about how best to move the needle in GYN cancer therapeutics. We have a lot of work to do, but the future is bright for our patients! 🌟 MD Anderson Cancer Center Nicole D. Fleming MD Larissa Meyer Lauren Cobb, MD

In honor of Research Appreciation Day, we encourage all SGO members to dive into the @GynCancer blog that has been spotlighting incredible researchers over the past few months. Learn more: foundationforwomenscancer.org/news-stories/f…

"No matter what phase of care someone is in, we should always provide hope" Your words. Our inspiration. We will miss you Dr. Michael Frumovitz-but your light and your beautiful spirit will shine on. Thank you for all that you have given to us. In life and beyond, keep Ovarcoming💙

Great talk on special considerations for immunotherapy clinical trials by my mentor Amir Jazaeri at the AACR ASCO Methods in Clinical Cancer Research course in La Jolla! 🧬🥼🧪

Excited to share our QI paper published in AJOG. If you’re not already adding metronidazole to cefazolin for SSI prophylaxis in Gyn surgery, you should start! Adjusted OR for SSI 0.49 ⬇️ with addition of metronidazole. Jolyn Taylor Kathleen Schmeler MD MD Anderson Cancer Center

Metronidazole and cefazolin vs cefazolin alone for surgical site infection prophylaxis in gynecologic surgery at a comprehensive cancer center ow.ly/WfE850TcmCF

Keys to happiness: 1. Exercise regularly 2. Cherish EVERY DAY 3. NEVER compare yourself to others 4. Don't live in the past 5. Compliment others 6. Don't attempt to be rational with irrational people 7. Be grateful for what you HAVE 8. Daily professional improvement

Thank you IJGC for the opportunity to feature our work!

#LeadArticle Racial and sociodemographic disparities in the use of targeted therapies in advanced ovarian cancer patients with Medicare by Anne Knisely, MD 🔎 bit.ly/4hAl1xq Pedro T Ramirez Arthur_HC_Hsu Aarthi S Jayraj Andreina Fernandes IGCS ESGO European Network of Young Gynae Oncologists

Another amazing winter SGO meeting in the books! ❄️⛷️ Thank you SGO for the opportunity to present our research on the prognostic effect of inactivating PPP2R1A somatic mutations on survival in uterine cancer patients receiving immunotherapy #SGOMtg MD Anderson Cancer Center

Join us in celebrating Moffitt Physician in Chief Karen Lu, MD, as she steps into her role as President of The Society of Gynecologic Oncology! As a nationally recognized-physician scientist with more than 15 years of health care leadership experience, this opportunity highlights

Thrilled to share our paper now out in nature that correlates inactivating PPP2R1A somatic mutations with improved survival for patients with cancer receiving immunotherapy, with exciting prelim mechanistic insights! Amir Jazaeri Linghua Wang, MD, PhD Yibo nature.com/articles/s4158…